Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk

Dashboard · Roster · MNC Pharma · Johnson & Johnson Taiwan

№ 97 · The Johnson & Johnson Taiwan dossier

Johnson & Johnson Taiwan

嬌生台灣

Parent: Johnson & Johnson (NYSE: JNJ)

Readiness

Held

Capped at 95. High confidence — AOR sourced within 0y · high-confidence research.

Workspace · saved locally in your browser

Pipeline status

Your notes · Johnson & Johnson Taiwan

Saves on blur. Stored in your browser only — not synced.

J&J post-2023 = Innovative Medicine (pharma) + MedTech (devices, vision, surgery) only. Consumer Health spun off as Kenvue (separate company NYSE: KVUE) in 2023. J&J Innovative Medicine TW is HCP-channel-led (oncology, immunology, neuroscience, infectious disease). MedTech TW is B2B surgeon/specialist-led. ACUVUE consumer is the most consumer-facing surface. WPP is fresh global media incumbent on Innovative Medicine since Dec 2024.

Signal timeline · last 90 days

0 of 0 shown

No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.

The arithmetic of 45

score breakdown

Intel depth (6 wedges · recent)	research_depth	+45
Total · capped 95		45

30-day signal trajectory

0 signals · spend N/A

Intel wedges

6 of 8 wedges corroborated. Research confidence: high — WPP J&J Dec 2024 US/Canada media win publicly documented across AdAge, MM+M, More About Advertising, MediaPost. Kenvue Dec 2025 WPP creative + Publicis media split also publicly documented (AdWeek, AdAge, Campaign)..

Open playbook →